Get the Stockscreener App
46.41
2.80%
-1.3271
Kymera Therapeutics Inc stock is traded at $46.41, with a volume of 85,928.
It is down -2.80% in the last 24 hours and down -0.15% over the past month.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
See More
Previous Close:
$47.74
Open:
$47.37
24h Volume:
85,928
Relative Volume:
0.21
Market Cap:
$3.09B
Revenue:
$87.56M
Net Income/Loss:
$-167.47M
P/E Ratio:
-16.82
EPS:
-2.76
Net Cash Flow:
$-148.20M
1W Performance:
+0.92%
1M Performance:
-0.15%
6M Performance:
+47.03%
1Y Performance:
+123.41%
1-Day Range:
$46.03
$47.76
1-Week Range:
$46.03
$49.35
52-Week Range:
$20.32
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Name
Kymera Therapeutics Inc
Sector
Industry
Phone
857-285-5314
Address
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
46.42 | 3.09B | 87.56M | -167.47M | -148.20M | -2.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.74 | 119.71B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.12 | 82.77B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
620.93 | 37.02B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.31 | 32.26B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.73 | 28.24B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | Stephens | Overweight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Aug-26-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Apr-22-24 | Initiated | Oppenheimer | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Jan-04-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-24 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-19-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-30-23 | Initiated | Truist | Buy |
| May-05-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Dec-06-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-08-22 | Initiated | Raymond James | Mkt Perform |
| Aug-15-22 | Initiated | Jefferies | Buy |
| Aug-03-22 | Initiated | Goldman | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Mar-10-22 | Initiated | JP Morgan | Neutral |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Sep-30-21 | Initiated | B. Riley Securities | Neutral |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Dec-04-20 | Initiated | H.C. Wainwright | Buy |
| Sep-15-20 | Initiated | BofA Securities | Neutral |
| Sep-15-20 | Initiated | Cowen | Outperform |
| Sep-15-20 | Initiated | Guggenheim | Buy |
| Sep-15-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Kymera Therapeutics Inc Stock (KYMR) Latest News
Kymera therapeutics director Pamela Esposito sells shares worth $122,500 - Investing.com
Wells Fargo Upgrades Kymera Therapeutics (KYMR) - MSN
Fred Alger Management LLC Makes New $859,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Fmr LLC Has $241.82 Million Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Intech Investment Management LLC Invests $650,000 in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Intech Investment Management LLC Makes New $650,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Purchased by Eventide Asset Management LLC - MarketBeat
14,378 Shares in Kymera Therapeutics, Inc. (NASDAQ:KYMR) Bought by Natixis Advisors LLC - MarketBeat
Natixis Advisors LLC Purchases Shares of 14,378 Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics announces proposed underwritten offering - MSN
Kymera Therapeutics to Participate in Upcoming December Investor Conferences - The Manila Times
Kymera Therapeutics to Present at Major Healthcare Investment Conferences in December | KYMR Stock News - StockTitan
Massachusetts Financial Services Co. MA Purchases 47,507 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
(KYMR) Trading Report - Stock Traders Daily
Jennison Associates LLC Purchases 368,394 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - MarketBeat
Stephens Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Coverage Initiated by Analysts at Stephens - MarketBeat
US Bancorp DE Sells 651 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Shares Down 6.7%Here's What Happened - MarketBeat
Avoro Capital Advisors LLC Expands Stake in Kymera Therapeutics Inc - GuruFocus.com
Long Term Trading Analysis for (KYMR) - Stock Traders Daily
FMR LLC Bolsters Stake in Kymera Therapeutics Inc - GuruFocus.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $51.21 Average Price Target from Analysts - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $49.00 at Morgan Stanley - Defense World
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $51.21 - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Kymer - GuruFocus.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call Transcript - Insider Monkey
Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times
Kymera Therapeutics to Present at 5 Major Healthcare Investor Conferences in November | KYMR Stock News - StockTitan
Mirae Asset Global Investments Co. Ltd. Boosts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
UBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat
Immunology to take front seat at Kymera - The Pharma Letter
Earnings call: Kymera Therapeutics advances in immunology and oncology By Investing.com - Investing.com Australia
Earnings call: Kymera Therapeutics advances in immunology and oncology - Investing.com India
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report - Yahoo Finance
FY2024 Earnings Estimate for KYMR Issued By Leerink Partnrs - Defense World
Leerink Partnrs Issues Optimistic Estimate for KYMR Earnings - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
(KYMR) Long Term Investment Analysis - Stock Traders Daily
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus - MSN
Guggenheim Increases Kymera Therapeutics (NASDAQ:KYMR) Price Target to $52.00 - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results - MarketBeat
The Latest Analyst Ratings For Kymera Therapeutics - Benzinga
Kymera Therapeutics (NASDAQ:KYMR) Receives "Buy" Rating from Truist Financial - MarketBeat
Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
B.Riley boosts Kymera stock target amid cautious optimism for STAT6 degrader - Investing.com Australia
Kymera Therapeutics stock target lifted by Stifel, buy rating on oncology pivot - Investing.com UK
Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Kymera Therapeutics Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com Canada
Kymera Therapeutics Inc Stock (KYMR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):